Navigation Links
Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
Date:5/7/2008

ently and with partners, including Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the protocol, design, scope, enrollment and other aspects of current and planned clinical trials and other studies of Arena's or its collaborators' product candidates and compounds; the future results of clinical trials; the tolerability, side effects, efficacy and potential of Arena's or its collaborators' product candidates and compounds; an NDA submission for lorcaserin and the potential partnering and commercialization of the drug candidate; expectations relating to the agreements and Arena's relationship with Siegfried; the advancement and content of Arena's pipeline; and other statements about Arena's outlook, strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, the timing and receip
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... According to Ross Selinger, President of Selinger ... the national office market continues to be strong, driven by ... by the third quarter’s surprising 3.9% GDP, unemployment decreasing to ... have held inflation down and the Fed is keeping interest ... remaining soft. , This solid economic news is having a ...
(Date:12/24/2014)... , Dec. 23, 2014 China ... the "Company"), a leading fully integrated plasma-based biopharmaceutical ... announced that its majority-owned subsidiary, Shandong Taibang Biological ... ("GMP") certification from the China Food and Drug ... production facility. As previously disclosed in the Company,s ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014  NeuroLifeSciences ... of mazindol in children with attention deficit/hyperactivity disorder published ... 2014 . The paper, titled "Pilot ... deficit/hyperactivity disorder" ( Konofal et al, Drug ... 2014 ) shows that mazindol might be an ...
(Date:12/22/2014)... DIEGO , Dec. 22, 2014 GenomeDx ... the Decipher Prostate Cancer Classifier, a genomic test for ... in node-negative, high-risk men managed by radical prostatectomy without ... radical prostatectomy is relatively uncommon, using tumor genomics to ... of metastatic disease is an important advance. The study ...
Breaking Biology Technology:ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3
... KONG, Aug. 23, 2011 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation ... plan to release financial results for the first quarter of ... close in the US. The Company will hold ... 30, 2011 to discuss its financial performance and give a ...
... FMC ) announced today its Agricultural Products ... development and supply of Chr. Hansen biological products for ... year of Chr. Hansen,s Nemix bacillus product in Brazil ... products in the Americas and key agricultural markets. ...
... YORK, Aug. 23, 2011 Reportlinker.com ... report is available in its catalogue: ... Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & ... (2010-2015) http://www.reportlinker.com/p0595074/Biochips-Market-DNA-Microarrays-Lab-on-Chip-Protein-Microarrays-Tissue--Cell-Arrays-Trends--Global-Forecast-2010-2015.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics ...
Cached Biology Technology:China Cord Blood Corporation to Report First Quarter Fiscal 2012 Financial Results 2FMC Corporation Announces Exclusive Global Development and Supply Agreements for Chr. Hansen Biological Products 2Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 2Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 3Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 4Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 5Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 6Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 7Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 8Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 9Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 10Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 11Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 12Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 13
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a ... announced that its DigitalPersona ® Pro Enterprise ... have been deployed throughout First Bank branch locations ... South Carolina and Virginia. First Bank, ... Southern Pines, North Carolina , selected ...
(Date:11/21/2014)... , November 18, 2014 ... Systems Market by Systems (Video, RFID, Access Control, Intrusion ... Factories, Hotels, Banks, Government), Component Service Geography - Global ... Systems Market is projected to be around $25 Billion ... by 2020, growing at a CAGR of 8.69%. ...
(Date:11/21/2014)... 20, 2014 C-Labs LLC, a leading provider ... Things (IoT), today announced the appointment of John ... Previously a strategic advisor to the firm, Mr. Traynor ... Traynor is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... A new finding reveals that African-American patients with ... than patients of other races with these cancers, even ... factors are controlled for. The finding, an analysis of ... to biological or genetic factors as the potential source ...
... Researchers at the University of Alabama at Birmingham ... bones grow and remodel themselves to stay strong, a ... new osteoporosis drugs, the researchers said The coupling ... beta-1, or TGF beta-1. Previously, scientists had searched for ...
... - Funxional Therapeutics Ltd (Funxional) has announced today the successful ... , an orally available small molecule which belongs to a ... ). , , The Phase I, single ascending dose ... tolerated at all doses studied and no serious adverse events ...
Cached Biology News:Genetic factors implicated in survival gap for breast, ovarian or prostate cancer 2Genetic factors implicated in survival gap for breast, ovarian or prostate cancer 3UAB study reveals bone coupling factor key to skeletal health 2Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action 2
... PYREX Delong style shaker flasks have three ... agitation of solutions to improve oxygen or ... reciprocating shakers. The long neck reduces splashing ... Their uniform wall thickness provides the proper ...
... numbers of samples may be carried out using ... requires minimum operator attention. System control and ... interface CE 4900. The elegant, powerful and ... XP and Windows 98 and 2000., The supplied ...
... cells were cultured in Minimum Essential Medium (Eagle) ... log phase of growth. In order to ... were fixed in acetone-methanol. The cells are ... slide, with each wells surface specifically treated to ...
Mouse polyclonal antibody to REXO4 - XPMC2 prevents mitotic catastrophe 2 homolog (Xenopus laevis)...
Biology Products: